• 1. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Latest Research on 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid (CAS: 890591-84-1) in Chemical Biology and Pharmaceutical Applications

3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid (CAS: 890591-84-1) is a pyrazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound belongs to a class of heterocyclic molecules known for their diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. Recent studies have focused on elucidating its molecular mechanisms, optimizing its synthesis, and exploring its therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid as a modulator of protein-protein interactions (PPIs) in cancer cells. The researchers demonstrated that this compound selectively inhibits the interaction between p53 and MDM2, a key regulatory pathway in tumor suppression. The study utilized X-ray crystallography to reveal the binding mode of the compound within the p53-MDM2 interface, providing structural insights for further optimization.

In the field of infectious diseases, a recent preprint (2024) on bioRxiv explored the antimicrobial properties of 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid against multidrug-resistant Gram-positive bacteria. The compound showed promising activity against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 8 μg/mL. Mechanistic studies suggested that it disrupts bacterial cell wall biosynthesis by targeting undecaprenyl diphosphate synthase (UPPS), an essential enzyme in peptidoglycan synthesis.

From a synthetic chemistry perspective, a novel and scalable route for the production of 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid was reported in Organic Process Research & Development (2023). The improved method features a one-pot condensation of 4-ethylbenzaldehyde with ethyl acetoacetate, followed by cyclization and oxidation, achieving an overall yield of 78% with high purity (>99.5%). This advancement addresses previous challenges in large-scale production of this compound.

Pharmacokinetic studies published in European Journal of Pharmaceutical Sciences (2023) evaluated the ADME (absorption, distribution, metabolism, and excretion) properties of 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid in rodent models. The compound exhibited favorable oral bioavailability (62%) and a plasma half-life of 4.2 hours, suggesting potential for oral administration in therapeutic applications. However, the study noted significant species differences in metabolic clearance that warrant further investigation.

Emerging computational approaches have been applied to understand and predict the biological activities of this compound. A 2024 study in Journal of Chemical Information and Modeling employed machine learning models trained on pyrazole derivatives to predict new biological targets for 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid. The models identified potential interactions with carbonic anhydrase IX, a target relevant to cancer and other diseases, which was subsequently validated experimentally.

In conclusion, recent research on 3-(4-Ethylphenyl)-1H-pyrazole-5-carboxylic acid (CAS: 890591-84-1) demonstrates its multifaceted potential in pharmaceutical development. While significant progress has been made in understanding its mechanisms and optimizing its synthesis, further studies are needed to fully explore its therapeutic applications and address remaining challenges in drug development. The compound represents an interesting scaffold for the design of novel therapeutic agents across multiple disease areas.

• 1134-49-2(5-phenyl-1h-pyrazole-3-carboxylic acid)
• 5071-61-4(3-Phenyl-1H-pyrazole-5-carboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)